Drug reference

Axitinib

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1044

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Drug Action

Axitinib is a tyrosine kinase inhibitor.

PDF page 1044

Indications And Dose

Treatment of advanced renal cell carcinoma following failure of previous treatment with sunitinib or a cytokine (aldesleukin or interferon alfa) ▶BY MOUTH ▶Adult: (consult product literature)

PDF page 1044

Contra Indications

Recent active gastro-intestinal bleeding. untreated brain metastases

PDF page 1044

Cautions

Hypertension (blood pressure should be well- controlled before starting and monitored during treatment)

PDF page 1044

National Funding Access Decisions

NICE decisions ▶Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatment (February 2015) NICE TA333 Axitinib (Inlyta ®) is recommended as an option for treating adults with advanced renal cell carcinoma after failure of treatment with a ﬁrst-line tyrosine kinase inhibitor or a cytokine, only if the manufacturer provides axitinib with the discount agreed in the patient access scheme. www.nice.org.uk/guidance/ta333

PDF page 1044

Safety

Important Safety Information

RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES See Cytotoxic drugs p. 938.

PDF page 1044

Interactions

→Appendix 1: axitinib

PDF page 1044

Side Effects

▶Common or very common Alopecia. anaemia. appetite decreased. arthralgia. asthenia. constipation. cough. dehydration. diarrhoea. dizziness. dysphonia. dyspnoea. electrolyte imbalance. embolism and thrombosis. gastrointestinal discomfort. gastrointestinal disorders. haemorrhage. headache. heart failure. hyperbilirubinaemia. hypertension. hyperthyroidism. hypothyroidism. mucositis. myalgia. nausea. oral disorders. oropharyngeal pain. pain in extremity. polycythaemia. proteinuria. renal failure. skin reactions. taste altered. thrombocytopenia. tinnitus. vomiting. weight decreased ▶Uncommon Leucopenia. neutropenia. posterior reversible encephalopathy syndrome (PRES)

PDF page 1044

Conception And Contraception

Effective contraception required during and for up to 1 week after treatment.

PDF page 1044

Pregnancy

Manufacturer advises avoid unless potential beneﬁt outweighs risk (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 1044

Hepatic Impairment

Manufacturer advises avoid in severe impairment—no information available. Dose adjustments Manufacturer advises reduce dose in moderate impairment.

PDF page 1044

Monitoring Requirements

▶Monitor for thyroid dysfunction. ▶Monitor haemoglobin or haematocrit before and during treatment. ▶Monitor for symptoms of gastro-intestinal perforation. ▶Monitor for symptoms of ﬁstula. ▶Monitor for proteinuria before and during treatment. ▶Monitor liver function before and during treatment.

PDF page 1044

Dose and formulations

Medicinal Forms

There can be variation in the licensing of different medicines containing the same drug. Tablet CAUTIONARY AND ADVISORY LABELS 25 ▶Inlyta (Pfizer Ltd) Axitinib 1 mg Inlyta 1mg tablets | 56 tablet P £703.40 (Hospital only) Axitinib 3 mg Inlyta 3mg tablets | 56 tablet P £2,110.20 (Hospital only) Axitinib 5 mg Inlyta 5mg tablets | 56 tablet P £3,517.00 (Hospital only) Axitinib 7 mg Inlyta 7mg tablets | 56 tablet P £4,923.80 (Hospital only)

PDF page 1044

Dose text by age group

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1044

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.

Drug reference

Axitinib

BNF 80 (2020–2021)

Source: BNF 80 (2020–2021)
PDF pages: 1044

Review source pages for extracted sections and age labels. BNF dose snippets show only their first line.

Overview

Drug Action

Axitinib is a tyrosine kinase inhibitor.

PDF page 1044

Indications And Dose

Treatment of advanced renal cell carcinoma following failure of previous treatment with sunitinib or a cytokine (aldesleukin or interferon alfa) ▶BY MOUTH ▶Adult: (consult product literature)

PDF page 1044

Contra Indications

Recent active gastro-intestinal bleeding. untreated brain metastases

PDF page 1044

Cautions

Hypertension (blood pressure should be well- controlled before starting and monitored during treatment)

PDF page 1044

National Funding Access Decisions

PDF page 1044

Safety

Important Safety Information

RISKS OF INCORRECT DOSING OF ORAL ANTI-CANCER MEDICINES See Cytotoxic drugs p. 938.

PDF page 1044

Interactions

→Appendix 1: axitinib

PDF page 1044

Side Effects

PDF page 1044

Conception And Contraception

Effective contraception required during and for up to 1 week after treatment.

PDF page 1044

Pregnancy

Manufacturer advises avoid unless potential beneﬁt outweighs risk (toxicity in animal studies). See also Pregnancy and reproductive function in Cytotoxic drugs p. 938.

PDF page 1044

Hepatic Impairment

Manufacturer advises avoid in severe impairment—no information available. Dose adjustments Manufacturer advises reduce dose in moderate impairment.

PDF page 1044

Monitoring Requirements

PDF page 1044

Dose and formulations

Medicinal Forms

PDF page 1044

Dose text by age group

Adult

(consult product literature)

First-line fragment. Read the complete Indications and Dose section above.

PDF page 1044

Age labels are extracted for navigation. Check the complete source section and current local guidance before clinical use.